Head-To-Head Survey: Intelligent Bio Solutions (NASDAQ:INBS) & Sanara MedTech (NASDAQ:SMTI)

Sanara MedTech (NASDAQ:SMTI) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Sanara MedTech and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%

Volatility and Risk

Sanara MedTech has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.31, suggesting that its share price is 331% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sanara MedTech and Intelligent Bio Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12 million	2.94	-$37.56 million	($3.59)	-9.20
Intelligent Bio Solutions	$4.22 million	1.29	-$12.43 million	($9.02)	-0.18

Intelligent Bio Solutions has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Sanara MedTech and Intelligent Bio Solutions, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1	4	0	0	1.80
Intelligent Bio Solutions	1	1	0	0	1.50

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential upside of 6.00%. Given Sanara MedTech’s stronger consensus rating and higher possible upside, research analysts plainly believe Sanara MedTech is more favorable than Intelligent Bio Solutions.

Insider and Institutional Ownership

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sanara MedTech beats Intelligent Bio Solutions on 10 of the 13 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.